Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.
The company’s obesity and diabetes franchise remained its biggest growth engine in the second quarter, with blockbuster GLP-1 drugs Mounjaro and Zepbound generating a combined $14.9 billion in revenue.